A better approach to monitoring of therapy in von Willebrand disease?

Emmanuel J. Favaloro

doi:10.1160/TH08-07-0449

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 100(03): 371-373
DOI: 10.1160/TH08-07-0449

Editorial Focus

Schattauer GmbH

A better approach to monitoring of therapy in von Willebrand disease?

Emmanuel J. Favaloro

¹Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, We stmead, New South Wales, Australia

› Author Affiliations

Abstract

Full Text

References

References
1 Sadler JE, Budde U, Eikenboom JCJ. et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 04: 2103-2114.
2 Favaloro EJ. Laboratory identification of von Willebrand Disease: Technical and scientific perspectives. Semin Thromb Hemost 2006; 32: 456-471.
3 Favaloro EJ. An update on the von Willebrand factor collagen binding (VWF:CB) assay: 21 years of age and beyond adolescence, but not yet a mature adult. Semin Thromb Hemost 2007; 33: 727-744.
4 Favaloro EJ. The utility of the PFA -100 in identification of von Willebrand Disease: A concise review. Semin Thromb Hemost 2006; 32: 537-545.
5 Nichols WL, Hultin MB, James AH. et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
6 Budde U, Metzner HJ, Müller HG. Comparative analysis and classification of von Willebrand factor/ factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost 2006; 32: 626-635.
7 Mazurier C. Composition, quality control, and labeling of plasma-derived products for the treatment of von Willebrand disease. Semin Thromb Hemost 2006; 32: 529-536.
8 Favaloro EJ, Bonar R, Kershaw G. et al. Reducing errors in identification of von Willebrand disease: The experience of the Royal college of Pathologists of Australasia Quality Assurance Program. Semin Thromb Hemost 2006; 32: 505-513.
9 Favaloro EJ, Bonar R, Meiring M. et al. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of Type 2B VWD. Thromb Haemost 2007; 98: 346-358.
10 Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 2006; 32: 485-491.
11 Kitchen S, Jennings I, Woods TA. et al. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost 2006; 32: 492-498.
12 Favaloro EJ, Grispo L, Exner T. et al. Development of a simple collagen binding assay aids in the diagnosis of, and permits sensitive discrimination between, Type I and Type II von Willebrand's disease. Blood Coagul Fibrinolysis 1991; 02: 285-291.
13 Favaloro EJ, Dean M, Grispo L. et al. von Willebrand's Disease: Use of Collagen Binding Assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy. Am J Hematol 1994; 45: 205-211.
14 Favaloro EJ, Kershaw G, Bukuya M. et al. Laboratory diagnosis of von Willebrand Disorder (VWD) and monitoring of DDAVP therapy: Efficacy of the PFA-100® and VWF:CBA as combined diagnostic strategies. Haemophilia 2001; 07: 180-189.
15 Favaloro EJ. Laboratory monitoring of therapy in von Willebrand Disease: Efficacy of the PFA -100® and VWF:CB as coupled strategies. Semin Thromb Hemost 2006; 06: 566-576.
16 Michiels JJ, van de Velde A, van Vliet HH. et al. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin Thromb Hemost 2002; 28: 111-132.
17 Michiels JJ, Berneman Z, Gadisseur A. et al. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD. Clin Appl Thromb Hemost 2006; 12: 277-295.
18 Michiels JJ, van Vliet HH, Berneman Z. et al. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Clin Appl Thromb Hemost 2007; 13: 14-34.
19 van Vliet HHDM, Kappers-Klunne MC, Leebeek FWG. et al. PFA-100 monitoring of von Willebrand factor (VWF) responses to DDAVP and FVIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. Thromb Haemost 2008; 100: 462-468.
20 Favaloro EJ, Lloyd J, Rowell J. et al. A cross-over, multi centre study to compare pharmacokinetics of two factor concentrates (Biostate® and AHF (High Purity)) in people with von Willebrand disorder. Thromb Haemost 2007; 97: 922-930.
21 Favaloro EJ, Kershaw G, McLachlan AJ. et al. Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease. Semin Thromb Hemostas 2007; 33: 745-758.
22 Favaloro EJ, Bukuya M, Martinelli T. et al. A comparative multi-laboratory assessment of factor concentrate and implications for clinical efficacy as potential replacement therapy in von Willebrand’s Disease (VWD). Thromb Haemost 2002; 87: 466-476.